Mohit Bansal
Stock Analyst at Wells Fargo
(4.16)
# 339
Out of 5,182 analysts
200
Total ratings
64.66%
Success rate
9.13%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgrades: Overweight | $200 → $250 | $180.67 | +38.37% | 17 | Apr 20, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $135 → $150 | $110.23 | +36.08% | 14 | Mar 12, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $250 | $201.22 | +24.24% | 4 | Feb 25, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $64.49 | +16.30% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $340.18 | +10.24% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $53.81 | +39.39% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $128.04 | +36.68% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $127.75 | +29.16% | 14 | Feb 11, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $57.78 | +3.84% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $868.27 | +47.42% | 19 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $745 → $800 | $744.44 | +7.46% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $4.04 | +23.76% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.86 | +330.11% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $426.01 | +20.89% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $26.99 | +103.78% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $197.38 | +31.73% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $40.81 | -14.24% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $102.06 | +46.97% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $54.26 | -13.38% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $22.12 | +35.62% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $37.28 | +87.77% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.79 | +11.98% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $26.74 | +6,911.97% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $7.72 | +366.32% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $7.97 | +138.39% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.47 | +3,981.63% | 4 | Dec 3, 2019 |
Biogen
Apr 20, 2026
Upgrades: Overweight
Price Target: $200 → $250
Current: $180.67
Upside: +38.37%
Merck & Co.
Mar 12, 2026
Maintains: Overweight
Price Target: $135 → $150
Current: $110.23
Upside: +36.08%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $235 → $250
Current: $201.22
Upside: +24.24%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $64.49
Upside: +16.30%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $340.18
Upside: +10.24%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $53.81
Upside: +39.39%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $128.04
Upside: +36.68%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $127.75
Upside: +29.16%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $57.78
Upside: +3.84%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $868.27
Upside: +47.42%
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $744.44
Upside: +7.46%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $4.04
Upside: +23.76%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.86
Upside: +330.11%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $426.01
Upside: +20.89%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $26.99
Upside: +103.78%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $197.38
Upside: +31.73%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $40.81
Upside: -14.24%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $102.06
Upside: +46.97%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $54.26
Upside: -13.38%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $22.12
Upside: +35.62%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $37.28
Upside: +87.77%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.79
Upside: +11.98%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $26.74
Upside: +6,911.97%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $7.72
Upside: +366.32%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $7.97
Upside: +138.39%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.47
Upside: +3,981.63%